September 21, 2021
Poor liquidity and risk have had built on market instability
Pre-open indications: 5 BUY and 1 SELLs
What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity!
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
September 17, 2021
When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping there is NO clinical trial initiation after a year and a half (1.5 years)? <read more)
September 20, 2021
The Biostage (BSTG) Chronicles: On Monday, 563 dropped the share price -$0.26 to $3.40 after Friday, 229 traded shares dropped the share price -$0.38 to $3.63 after Thursday’s -$0.04 with 461 shares traded, suddenly 14,641 were traded with the shares down -$0.04. Proves my facts of the “pump/promote” actions; why hasn’t the SEC questioned who or which entity is buying these shares – there is a definite pattern?
Preopen indication results: 6 Hits and 0 MISS
My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.
It's a daunting task to understand risk, seeing the unforeseen; on the basis of my own “rules”, I set-up my own “warning analysis” which isn’t machine oriented!
September 17, 2021
When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response! Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping there is NO clinical trial initiation after a year and a half (1.5 years)? <read more)
August 20, 2021
What’s true, false, misleading, unresolved and unanswered issues with SLOPPY if any follow-through to date? Critical issue: still subject to “Going Concern” label due to lack of financing, low cash position and “runway” HUGE deficit to date: $70.2 million with NO clinical TRIAL initiation with a year and a one-half old approved IND … it’s NOT about COVID stoppage, there are NOT any clinical employees left and NO monies to initiate?
August 16, 2021
A scorecard of of 35 covered companies and date of releases (to date). The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status" Reported to today ... with a LPS (loss-per-share) tag - Athersys (ATHX), bluebird bio (BLUE), Precigen (PGEN), Regenxbio (RGNX), Voyager Therapeutics (VYGR), BioLife Solutions (BLFS), Bellicum Pharmaceuticals (BLCM), Homology Medicine (FIXX), Chinook Therapeutics (KDNY), Biostage (BSTG), Solid Biosciences (SLDB) to date
© 2021 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
